Other News

U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label

CAMZYOS is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the underlying source of obstructive HCM VALOR-HCM is the second Phase 3 trial in which CAMZYOS demonstrated significant improvement in symptoms of obstructive HCM June 15, 2023 08:23 PM Eastern Daylight Time PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced […]

Endologix Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting

The DETOUR 2 study is a prospective, single-arm, international, multi-center clinical evaluation of the novel DETOURTM System for fully percutaneous femoropopliteal bypass procedures. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the 24-month results […]

VESTECK, Inc. is excited to announce that the U.S. Patent Application No. 17/841,373 Title: REMOTE SURGICAL SUTURE SYSTEM, has been allowed by the U.S. Patent and Trademark Office (USPTO)

WEST CHESTER, Pa., June 15, 2023 /PRNewswire/ — VESTECK (WWW.VESTECK.com) is a clinical stage medical device company focused on bringing a proprietary technology to the aortic repair and structural heart markets.  The “SUTURE-TIGHT™” catheter comes preloaded with 4 pair of nitinol sutures, it secures endovascular (EVAR/TEVAR) grafts to the aorta on initial implant […]

Core Sound Imaging Announces Studycast & EchoSolv™ Integration

Core Sound Imaging and Echo IQ finalize integration agreement for EchoSolv™ and the Studycast® system, through the Studycast Integration Program. This partnership enables Studycast clients to seamlessly integrate AI-powered detection of Aortic Stenosis into their imaging and reporting workflow. RALEIGH, N.C., June 14, 2023 /PRNewswire/ — Core Sound Imaging, Inc., creators of […]

Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease

Verve to Receive $60 Million in Combined Upfront Payment and Equity Investment; Additional Capital Positioned to Extend Verve’s Expected Cash Runway into 2026 Verve has Opt-in Rights to Co-fund and Share in Potential Margins of Products Resulting from the Collaboration BOSTON, June 15, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. […]

CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review

PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received the recommendation from the independent Data and Safety Monitoring Board […]

CardieX Selected for Medtech Innovator’s 2023 Accelerator Cohort

IRVIVE, Calif., June 14, 2023 /PRNewswire/ — Cardiovascular health technology company, CardieX Limited, is pleased to announce it has been selected as part of MedTech Innovator’s 2023 Accelerator Cohort. MedTech Innovator is recognized as the world’s largest accelerator of medical technology companies. More than 1,150 companies applied to participate in the 2023 Accelerator program […]

Philips’ direct-to-angio stroke pathway: new analysis demonstrates substantial cost savings in addition to improved patient outcomes

Economic analysis of cost of Vall d’Hebron University Hospital Stroke Unit shows direct-to-angio stroke pathway can save more than USD 3,000 per patient Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the results of a health economic analysis published in the Journal of NeuroInterventional […]

Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System

Addition to Pounce™ thrombectomy platform with the low-profile (LP) model will allow for efficient clot removal in below-the-knee peripheral arteries (2 mm to 4 mm), expanding the addressable market for the Pounce™ platform EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic […]